1. Introduction {#sec1}
===============

Recent estimates suggest that the worldwide prevalence of soil-transmitted helminths (STHs), including infection with *Ascaris lumbricoides*, *Trichuria trichuris* and hookworm, is 1.5 billion people ([@bib14]; [@bib33]; [@bib16]). The total estimated burden due to STHs is 3.4 million disability-adjusted life years ([@bib11]). The symptoms associated with STH infection are not specific and are usually more severe and debilitating in school-aged children and in the elderly. Children who are chronically infected can display malnutrition and developmental delay while elderly people infected with STHs often display reduced work-related productivity ([@bib5]).

Four drugs (albendazole, mebendazole, pyrantel pamoate, levamisole) are on the World Health Organization\'s list of essential medicines for the treatment of STH infections ([@bib41]). The two benzimidazoles (albendazole and mebendazole) are most commonly used drugs in preventive chemotherapy programs ([@bib41]; [@bib18]; [@bib1]). Ivermectin has a broad spectrum of activity against different parasites ranging from nematodes such as *Strongyloides stercoralis* or *A. lumbricoides* to filarial parasites, and arthropods and even affects the Anopheline vectors of malaria ([@bib24]; [@bib43]; [@bib12]; [@bib48]). Oxantel has high activity against *T. trichuris* ([@bib47]; [@bib13]; [@bib39]). Finally, tribendimidine has been shown to have a similar spectrum to that of albendazole, and could be an alternative to the latter in case of emergence of benzimidazole resistance ([@bib46]). There is growing consensus to use these drugs in combination to increase efficacy and decrease the risk of drug resistance.

Recent advancements in high-throughput sequencing technologies enable the characterization of the human microbiome ([@bib40]; [@bib3]; [@bib15]), which was not possible at the time those drugs were introduced. Thus, the interactions of these anthelminthic drugs and drug combinations with the human gut microbiota composed of a variety of microorganisms, including other eukaryotic parasites, protozoa, viruses, fungi and most importantly bacteria ([@bib29]; [@bib22]; [@bib36]), can now be studied. Drug-microbiota interactions can modulate the bioavailability and activity of drugs and hence modulate their efficacy ([@bib29]; [@bib9]; [@bib44]; [@bib8]; [@bib25]). STHs share the same environmental niche as the gut bacterial microbiota, but potential interactions between the gut microbiota and anthelminthic agents have not been assessed to date. The aim of this study was to identify potential interactions between these treatments and the non-target microbiota.

2. Methods {#sec2}
==========

2.1. Sample collection and ethics statement {#sec2.1}
-------------------------------------------

Samples were collected in the framework of a randomized, controlled, single blind, non-inferiority trial in the Agboville district in Côte d'Ivoire. Hookworm positive adolescents (age 15 to 18), confirmed by quadruplicate Kato-Katz thick smears, were randomly assigned to four treatment arms, including tribendimidine (400 mg), tribendimidine (400 mg) plus ivermectin (200 μg/kg), tribendimidine (400 mg) plus oxantel pamoate (25 mg/kg) and albendazole (400 mg) plus oxantel pamoate (25 mg/kg). Details about the study are presented elsewhere ([@bib27]). From each adolescent, one stool sample was collected prior to treatment, 24 h post-treatment and 3 weeks post-treatment, and a total of 144 stool samples were analyzed ([Table 1](#tbl1){ref-type="table"}).Table 1**Summary of volunteers investigated in this study.** From each adolescent of each of the four treatments, a sample was collected before, 24 h after and 3 weeks after treatment. EPG = Hookworm eggs per gram of stool, FU = follow-up.Table 1IDSamplesEPG (baseline)EPG (FU)IDSamplesEPG (baseline)EPG (FU)**Treatment arm 1Treatment arm 2**P- 5D6, E6, F6318426P- 6D8, E7, F71440P- 7D9, E8, F8300P- 17D21, E18, F18120P- 9D11, E10, F1096132P- 19D23, E20, F20840P- 10D12, E11, F1136228P- 23D27, E24, F2410020P- 11D13, E12, F12198108P- 27D31, E28, F28720P- 14D16, E15, F15780P- 33D42, E30, F305340P- 22D26, E23, F2345078P- 34D43, E31, F31780P- 26D30, E27, F27360P- 35D44, E44, F44420P- 29D34, E40, F401026P- 43D78, E45, F45300P- 32D39, E43, F4333654P- 46D91, E37, F37180P- 38D55, E33, F33780P- 48D95, E34, F3447400P- 41D76, E38, F382400**Treatment arm 3Treatment arm 4**P- 2D3, E3, F345066P- 1D1, E1, F14236P- 3D4, E4, F49660P- 4D5, E5, F596288P- 8D10, E9, F9186210P- 15D18, E16, F165340P- 12D14, E13, F131260P- 20D24, E21, F21660P- 13D15, E14, F14492108P- 21D25, E22, F2220490P- 16D20, E17, F17630516P- 24D28, E25, F2542624P- 18D22, E19, F19696282P- 25D29, E26, F2672108P- 28D33, E29, F2918240P- 31D37, E41, F41222204P- 30D35, E42, F4216981302P- 37D52, E46, F4625848P- 36D50, E47, F4722224P- 40D62, E36, F369120P- 39D58, E48, F486012P- 42D77, E39, F395820P- 44D79, E2, F22700P- 47D94, E32, F32258060P- 45D86, E35, F351680

Ethical approval was obtained from the Comité National d'Ethique et de la Recherche in Côte d'Ivoire (083/MSHP/CNER-kp) and the Ethics Committee of North-western and Central Switzerland (EKNZ UBE-15/35). The trial was registered with ISRCTN (number 14373201).

2.2. Sample collection {#sec2.2}
----------------------

For DNA isolation, 150--250 mg of stool sample was diluted in 500 μl of AVL buffer (Qiagen, Darmstadt, Germany) and subsequently homogenized using a soil-grinding SK38 kit on the Precellys 24 system (Bertin Technologies, Saint-Quentin, France). Homogenized samples were further extracted on a Magna Pure 96 system (Roche, Basel, Switzerland) using the DNA and Viral NA Large Volume kit (Roche, Basel, Switzerland) according to the manufacturers\' protocol.

2.3. 16S amplicon PCR {#sec2.3}
---------------------

2.5 μl of isolated DNA was used to perform amplification of the V3-V4 region using the following primer pair:Forward primer = 5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAGReverse primer = 5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC

The polymerase chain reaction (PCR) was performed in 25 μl reaction volumes using the 2X KAPA HiFi HotStar ReadyMix (KAPA Biosystems; Boston, MA, USA). The thermocycler was set as follows: 95 °C for 3 min, 25 cycles of 95 °C (30 s), 55 °C (30 s) and 72 °C (30 s), one additional step at 72 °C for 5 min and finally set on hold indefinitely at 4 °C. The quality of the amplified product was controlled visually on a 1% agarose gel. The amplicons were purified using an AMPure XP beads (Beckman-Coulter; Fullerton, CA, USA) protocol.

2.4. Sequencing {#sec2.4}
---------------

We used a Nextera XT Index kit (Illumina, San Diego, CA, United States of America) to perform the index PCR and generate barcoded pools of 96 samples. The amplification reaction was conducted on a thermocycler under the following condition: 95 °C for 3 min, 20 cycles of 95 °C for 30 s, 55 °C for 30 s, 72 °C for 30 s, one additional step at 72 °C for 5 min and a final step at 4 °C until further processing. Amplicons were cleaned with AMPure XP beads according to Illuminas\' library preparation guide. The quality of the product was assessed using a 1% agarose gel and the quantification was performed using a Qubit Fluorimeter (Life Technologies, Carlsbad, CA, United States of America) and the corresponding High-sensitivity DNA assays (Life Technologies, USA). The 96 amplicon samples were pooled together in an equimolar way and loaded on a cartridge on the Illumina Miseq sequencing platform (Illumina, USA). We used V3 reagents (2\*300bp) (Illumina, USA) for this experiment in 2\*300 base pair mode.

2.5. Data processing and statistical analysis {#sec2.5}
---------------------------------------------

Raw Fastq files were filtered using a quality score (Phred) above Q20. Filtered reads were fed in the QIIME pipeline ([@bib7]) v 1.9.1, which was configured for standard OTU picking (closed reference, Greengenes database v.13_8). Shannon diversity index was computed with QIIME using a rarefaction depth of 19500 sequences and principal component analysis (PCA) plots were generated with the STAMP statistical analysis package ([@bib31]) using Euclidean distance matrices. Taxonomic profiles were further analyzed with the PICRUSt suite ([@bib20]), in order to predict the functional content of the gut microbiota based on the abundance of 16S rRNA genes. To compare groups (treatment arms), we performed an analysis of variance using the STAMP software ([@bib31]), both for taxonomical and functional profiles. Benjamini-Hochberg correction ([@bib4]) was applied to the uncorrected statistics, to control for multiple testing bias. Statistical significance is reached with a corrected *p*-value (*q*-value) below 0.1.

3. Results {#sec3}
==========

3.1. Overall comparison of the taxonomic composition between treatment arms {#sec3.1}
---------------------------------------------------------------------------

Pre-processing, including filtering and denoising of the sequence datasets resulted in the analysis of a total of 2,311,784 high quality reads for the 48 pre-treatment samples (median = 55,000), 2,261,185 reads for the 48 samples collected 24 h after treatment (median = 56,826), and 2,580,596 filtered reads for the 48 samples collected in the follow-up period of 3 weeks (median = 59,889). We compared the overall microbiota diversity of all samples, grouped by treatment arm, using a principal component analysis and the Shannon diversity index, as shown in [Fig. 1](#fig1){ref-type="fig"}. Complete taxonomic profiles stratified by treatment arm are shown in [Supplementary Fig. 1](#appsec1){ref-type="sec"}.Fig. 1**Overall diversity comparison of taxonomic composition at the phylum level, stratified by treatment arm.** TA1 = Tribendimidine; TA2 = Tribendimidine plus ivermectin; TA3 = Tribendimidine plus oxantel pamoate; TA4 = Albendazole plus oxantel pamoate. Panel A: pre-treatment. Panel B: 24 h post-treatment. Panel C: 3 weeks post-treatment. Panel D shows the Shannon diversity index at each time point. h = hours; w = weeks.Fig. 1

Treatment groups were not associated with significant differences in taxonomic composition or Shannon diversity at any time-point. Although two samples (P-3 and P-8) from treatment arm 3 (tribendimidine plus oxantel pamoate) differed significantly from the rest of the population before treatment, there was no observable difference in gut bacterial composition of these two patients both at 24 h post-treatment and 3 weeks post treatment.

At 24 h after drug administration, the principal component analysis showed a homogeneous population and the SDI across all treatment arms was not significantly different. However, there was a noticeable spread (∼0.35--0.2) of samples belonging to treatment arm 2 over component 1 (x-axis), while samples from this group all clustered tightly before treatment (within coordinates −0.1 and ∼0.1 on both axis).

Finally, the observation of a generally homogeneous bacterial composition of the gut microbiota at the phylum level in the studied population was confirmed in the samples collected 3 weeks after administration of the treatments. According to the PCA, the sample collected from patient 39 differed from the rest of the population, at this sampling time. The SDI for this sample was low (SDI = 1.72) compared to the rest of the group.

3.2. Differences in taxonomic composition after administration of the four treatments {#sec3.2}
-------------------------------------------------------------------------------------

In order to assess the potential effect of each drug/drug combination tested in this study on the gut microbiota, we compared abundance means of each bacterial taxon between groups, at different taxonomic levels (phylum and family). At baseline, there was no phylum which was differentially abundant between the four treatment arms. 24 h after treatment, there was a significantly higher abundance (*q*-value \< 0.1) of species from the *Bacteroidetes* phylum in samples from treatment arm 2. The relative abundance of *Bacteroidetes* was greater in treatment arm 2 than all other groups 24 h after treatment, but not at baseline nor at 3 weeks.

In order to quantify the degree of variation of *Bacteroidetes* over time, we compared those from pre-to 24 h post-treatment samples and those from 24 h post-to 3 weeks post-treatment samples, as shown in [Fig. 2](#fig2){ref-type="fig"}.Fig. 2**Box plot showing the abundance variation of the phylum *Bacteroidetes*.** This plot summarizes variations of abundance of *Bacteroidetes* between two sampling times (from pre-treatment to 24 h post-treatment and 24 h to 3 weeks post-treatment), by treatment arm. Treatment arm 1 = Tribendimidine; Treatment arm 2 = Tribendimidine plus ivermectin; Treatment arm 3 = Tribendimidine plus oxantel pamoate; Treatment arm 4 = Albendazole plus oxantel pamoate.Fig. 2

In order to further characterize potential drug-bacteria interactions, we screened lower taxonomic levels and found two families, which follow a similar abundance pattern (A) to that of *Bacteroidetes* (A~TA2~\>A~TA1~ = A~TA3~ = A~TA4)~, namely S24_7 (recently renamed to *Candidatus homothermaceae* ([@bib30]),) and *Prevotellaceae*. However, for both families, the significance for inter-group difference was not reached (*q*-value \> 0.1).

3.3. Prediction of metabolic pathways {#sec3.3}
-------------------------------------

In order to highlight possible interactions, we compared the predicted abundance of metabolic pathways obtained with PICRUSt between the four treatment arms at each sampling time ([Fig. 3](#fig3){ref-type="fig"}).Fig. 3Box plot comparing the abundance of predicted metabolic pathways at the different sampling times. TA1 = Tribendimidine; TA2 = Tribendimidine plus ivermectin; TA3 = Tribendimidine plus oxantel pamoate; TA4 = Albendazole plus oxantel pamoate. Panel A shows the abundance of biotin metabolism, folate biosynthesis and N-glycan biosynthesis pathways before treatment, by treatment arm. Panel B shows the abundance of the three metabolic pathways, 24 h after administration of treatment. Panel C highlights the abundance of the three metabolic pathways, 3 weeks after administration of treatment. Significance is achieved with a *q*-value \< 0.1. *q*-values are shown only for comparisons which are significantly different.Fig. 3

In samples collected at baseline, the abundance of sequences related to biotin metabolism, folate, and N-glycan biosynthesis was the same across all treatment groups. The situation changed 24 h after treatment when these metabolic pathways became significantly more abundant in the tribendimidine-ivermectin treatment arm (*q*-values = 0.047, 0.016, and 0.038, for biotin metabolism, folate biosynthesis, and N-glycan biosynthesis, respectively). The abundance pattern was the same for each of the three pathways, the highest abundance being associated to treatment with tribendimidine in combination with ivermectin (treatment arm 2) and being lower for the three other groups. The situation after 3 weeks was similar to pre-treatment, and no differentially abundant pathway could be identified.

4. Discussion {#sec4}
=============

There is a growing interest in associations between the human microbiome and drug therapy, which has been called "pharmacomicrobiomics" ([@bib34]; [@bib42]; [@bib19]; [@bib45]). This study is the first investigating effects of different anthelminthic drugs and their combinations on the human gut microbiota of adolescents infected with hookworms in a tropical setting.

Several studies have shown that the effects of various parasitic infections on the gut microbiota are relatively modest ([@bib6]; [@bib17]; [@bib37]), yet, there is only scarce information about the impact, direct (= drug effect on bacterial composition) or indirect (= change in bacterial composition is due to clearance of the worm), of drugs used to treat parasitic infections on the gut microbiota. Cross-reaction of drugs designed to target eukaryotic parasites between the gut microbiota and various treatments (e.g. anti-cancerous drugs) has been shown ([@bib2]; [@bib35]), and given the fact STHs and gut bacteria share the same environment these effects are possible for anthelminthic drugs as well.

Our analyses indicate that tribendimidine given alone or together with oxantel pamoate, and the combination of albendazole and oxantel pamoate is not associated with any major changes in the taxonomic composition of the gut microbiota in this population, at both the short-term post-treatment (24 h) and long-term post-treatment (3 weeks) periods. However, treatment with tribendimidine in combination with ivermectin was found to be associated with shifts in the relative abundance of *Bacteroidetes*. This phylum increased in relative abundance in the first 24 h post-administration and decreased over the 3 weeks post-treatment. Within the *Bacteroidetes* phylum, two bacteria families, *Prevotellaceae* and *Candidatus Homeothermaceae* (former S24_7 ([@bib30])), accounted for most of the variation observed in the abundance of *Bacteroidetes*.

We assessed the potential metabolic significance of this taxonomic shift using PICRUSt prediction, which accurately infers metabolic gene content from taxonomic composition ([@bib21]). Of all predicted metabolic pathways, three were significantly more abundant in samples from treatment arm 2, namely, biotin metabolism, folate biosynthesis, and N-glycan biosynthesis, and all are involved at some point in the biosynthesis of B vitamins. While the statistical proof of higher abundance of *Prevotellaceae* and *Candidatus Homeothermaceae* in patients from treatment arm 2 (tribendimidine plus ivermectin) is somewhat weaker to that of *Bacteroidetes*, it has been shown that both groups present characteristics highly relevant to each of the three differentially abundant metabolic pathways. Indeed, and while acknowledging that it does not encompass the complete range of their activities in the gut, members from the *Prevotellaceae* family almost ubiquitously harbor the genes associated with B vitamin biosynthesis ([@bib23]). Similarly, one of the purposes of *Candidatus Homeothermaceae* in the gut of mammals is to regulate the synthesis of B vitamins ([@bib30]). Of note, a possible cause for the lack of statistical power for findings observed in our study for these two taxa is the intrinsically weak taxonomic resolution of 16S rRNA gene identification, which frequently does not allow categorizing sequences at lower taxonomic levels, in this case, the family level. High level of biotin, or vitamin B~7~, in rat livers, has been associated with decreased absorption of orally administered vitamin B~12~ ([@bib32]). For folate (vitamin B~9~), decreased concentrations in combinations with low B~12~ levels have been associated with various symptoms, including anemia ([@bib26]; [@bib38]), a common consequence of ivermectin administration ([@bib28]). However, in order to validate these observations and to understand these interactions in detail, additional studies investigating other parameters (e.g. monitoring of B vitamins levels after treatment) and tests with higher taxonomic resolution (e.g. strain identification with shotgun metagenomics) are required.

This study has limitations. Indeed, while the study design in its current form enables the identification of significant differences in the composition of the gut microbiota between different treatment groups, it does not allow distinguishing between direct or indirect effects. Future studies might be considered including treatment of uninfected patients and patients who received a placebo, although this might be challenging from an ethical point of view. However, it is worth highlighting that the observed effects (higher abundance of *Bacteroidetes* and specific metabolic pathways) are distributed homogeneously across all samples analyzed from the tribendimidine-ivermectin group, except for one sample measured 24 h post-treatment. Additionally, stable abundance of *Bacteroidetes* and the metabolic pathways is observed homogeneously across all samples from the other treatment groups, except for two samples. Both facts support the hypothesis of a re-compositional event triggered by the administration of tribendimidine plus ivermectin and rule out observed effects driven mainly by random outlying samples.

5. Conclusion {#sec5}
=============

In conclusion, our study revealed several key findings of antihelminthic drugs/microbiota interactions. Tribendimidine, tribendimidine plus oxantel pamoate and albendazole plus oxantel-pamoate do not cause microbiome-specific effects and hence are unlikely to cause variability in response. On the other hand, treatment with a combination of tribendimidine and ivermectin triggers a re-compositional event of the gut microbiota, which was not observed for the other treatments studied. Moreover, a higher abundance of *Bacteroidetes*, and to some extent, of bacteria from the *Prevotellaceae* and *Candidatus Homeothermaceae* families as well as an overrepresentation of metabolic pathways related to B vitamins biosynthesis, was observed in patients treated with tribendimidine and ivermectin, 24 h after treatment. Importantly, the observed effects are transient as they disappear within three weeks after administration of this anthelminthic treatment.
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